title: [New oral anticoagulants in the treatment of venous thromboembolism].
abstract: Rivaroxaban (with initial increased dosage) may be used as a stand-alone therapy in patients with venous thrombo-embolism. The development of new anticoagulant drugs opened several options in the management of venous thrombo-embolism. The efficacy and safety of these new oral anticoagulants in specific population as elderly and those with renal impairment deserve future research. At that time, only rivaroxaban is licensed in France, in the treatment of deep venous thrombosis.
authors.affiliation: Université Saint-Étienne, Jean-Monnet, groupe de recherche sur la thrombose, EA3065, 42000 Saint-Étienne, France; Inserm, CIE3, 42000 Saint-Étienne, France; CHU de Saint-Étienne, hôpital Nord, service de médecine et thérapeutique, Saint-Étienne, France. Electronic address: laurent.bertoletti@chu-st-etienne.fr.
authors.forename: Laurent
authors.initials: L
authors.lastname: Bertoletti
authors.forename: Jean-Christophe
authors.initials: JC
authors.lastname: Lega
authors.forename: Nathalie
authors.initials: N
authors.lastname: Moulin
authors.forename: Andréa
authors.initials: A
authors.lastname: Buchmuller
authors.forename: Patrick
authors.initials: P
authors.lastname: Mismetti
authors.forename: Hervé
authors.initials: H
authors.lastname: Decousus
mesh_terms: D000284:Administration, Oral; D000925:Anticoagulants / Q000008:administration & dosage*; D006801:Humans; D009025:Morpholines / Q000008:administration & dosage; D000069552:Rivaroxaban; D013876:Thiophenes / Q000008:administration & dosage; D054556:Venous Thromboembolism / Q000188:drug therapy*
chemical_list: D000925:Anticoagulants; D009025:Morpholines; D013876:Thiophenes; D000069552:Rivaroxaban